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Abstract
Summary: Results from hundreds of genome-wide association studies (GWAS) are now freely
available and offer a catalogue of the association between phenotypes across medicine with var-
iants in the genome. With the aim of using this data to better understand therapeutic mechanisms,
we have developed Drug Targetor, a web interface that allows the generation and exploration of
drug–target networks of hundreds of phenotypes using GWAS data. Drug Targetor networks con-
sist of drug and target nodes ordered by genetic association and connected by drug–target or
drug–gene relationship. We show that Drug Targetor can help prioritize drugs, targets and drug–
target interactions for a specific phenotype based on genetic evidence.
Availability and implementation: Drug Targetor v1.21 is a web application freely available online
at drugtargetor.com and under MIT licence. The source code can be found at https://github.com/
hagax8/drugtargetor.
Contact: helena.gaspar@kcl.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The number of genome-wide association studies (GWAS) is grow-
ing. Consortia are unravelling associations between genetic variants
and traits with ever increasing sample sizes. Available GWAS cover
many areas of medicine, behaviour and biology. In addition, initia-
tives such as the Genotype-Tissue Expression (GTEx) project (GTEx
Consortium, 2013) investigate the tissue-dependent variation in
gene expression levels and identify associations with expression
quantitative trait loci (eQTLs), and methods such as S-PrediXcan
(Barbeira et al., 2018) allow prediction of tissue-specific expression
levels using GWAS summary statistics. These advances can help
map GWAS associations to protein targets in a tissue-specific man-
ner. Maggiora and Gokhale (2017) have shown that bipartite drug–
target networks can be useful to assess polypharmacology (drugs
binding several targets) or polyspecificity (targets interacting with
dissimilar drugs), by providing a simple bipartite representation of
drug–target interactions. In this paper, we present Drug Targetor
(drugtargetor.com), a web interface that allows users to browse over
500 GWAS to identify drugs and targets of interest using bipartite
drug–gene networks. These networks are phenotype-dependent:
drugs and genes are ordered using GWAS-derived genetic scores.
Drug Targetor uses several data layers: drug–target interactions
(how a drug binds a target), drug–gene interactions (how a drug
influences gene expression), genetic scores to order drugs and genes
by association with a phenotype and predicted gene expression lev-
els derived from GWAS and eQTLs.
2 Materials and methods
2.1 Bipartite drug–target networks
Drug Targetor v1.21 builds phenotype-dependent bipartite drug–
gene networks using HTML 5 canvas and JavaScript
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(Supplementary Fig. S1). A bipartite network consists in two sets of
disjoint and independent sets of nodes A and B. Edges connect nodes
in A to nodes in B. In Drug Targetor networks, A ¼ drugs and
B ¼ genes. Drugs and genes are connected by type of drug–gene or
drug–target interaction (Table 1). Genes and drugs are ordered by
genetic scores derived from GWAS. The web platform allows to
choose the phenotype and tissue of interest, the drug ensemble to be
used and the type of drug–target or drug–gene interaction. A total of
530 phenotypes are available in the interface as of October 2018.
The drugs are subdivided into categories defined by the Anatomical
Therapeutic Chemical Classification System (ATC, https://www.
whocc.no/atc_ddd_index). Drug Targetor uses its own database of
genetic scores for drugs and genes; users can choose to visualize the
network for the top drugs, or a network corresponding to a specific
ATC drug class.
2.2 Phenotype-dependent drug and gene scores
Drugs and genes are ordered by GWAS-derived scores, which can be
used as filters in the network construction. The drug score is the
log10(P-value) of the drug/phenotype association test, computed
using MAGMA pathway analysis (de Leeuw et al., 2015) after map-
ping each drug to its interacting genes. Gene scores, on the other
hand, are a combination of two gene-wise tests (cf. Supplementary
Text S3 for details): MAGMA gene-wise association test and S-
PrediXcan (Barbeira et al., 2018) tissue–gene association test, which
uses eQTL data (Supplementary Text S4). The gene scores range
from 1 to 7; genes with the highest score (7) are significant in both
S-PrediXcan and MAGMA. Drug Targetor reports all S-PrediXcan
z-scores; positive or negative z-scores correspond to up- or down-
regulation in the tissue of interest.
2.3 Drug–target and drug–gene connections
Different types of interactions can be selected in Drug Targetor and
are used to connect drugs and targets: drug–gene interactions (how
a drug influences gene expression), and drug–target interactions
(how a drug interacts with a protein target). Drug–target interac-
tions are further divided into drug mechanism of action (antagonist,
agonist, modulator), and data measuring binding of a compound
to a target (Supplementary Text S1). Different colours are attributed
to the connections depending on interaction type (cf. Table 1).
The different data sources and their references are reported in
Supplementary Table S1.
3 Example
We present an example of a Drug Targetor network based on a type
2 diabetes GWAS (Scott et al., 2017) in Figure 1.
Drugs with highest score are represented with their top targets
(for gene filtering options, cf. Supplementary Text S5). Top-ranked
drugs include already known diabetes drugs agonists of the glitazone
receptor (PPARG gene), but also melatonin receptor 1B agonists.
A recent study showed an improvement of sleep quality in type 2
diabetes patients with insomnia treated with ramelteon (Tsunoda
et al., 2016); evidence also points towards a link between melatonin
and glucose homeostasis (Lardone et al., 2014). Drug Targetor sug-
gestions are supported by literature, indicating that such networks
could be suggestive of repurposing opportunities.
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Table 1. Graphical elements of Drug Targetor networks
Graphical element Description
Blue connector Agonist, positive modulator
Orange connector Antagonist, negative modulator
Brown connector Partial agonist
Purple connector Modulator
Black connector Interaction but unknown mechanism of action
Red connector Decreases gene expression
Green connector Increases gene expression
Grey connector Unknown effect on gene expression
Left-hand table
(drug table)
Drugs ordered by genetic score for a given
phenotype
Right-hand table
(gene table)
Genes ordered by genetic score for a given
phenotype
Red/green cells
(gene table)
Negative/positive tissue-dependent association
result
Fig. 1. Drug Targetor network representing top drugs and their targets with
drug and gene scores derived from a type 2 diabetes genome-wide associ-
ation study by Scott et al. (2017). Drug and gene scores were computed using
MAGMA. Tissue-wise gene associations (z-scores) in the gene table were
computed using S-PrediXcan
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